The company affirms its expectation to have 20m coronavirus vaccine doses available in the US by the end of 2020
- and expects to have between 100-125m doses available globally in Q1 of 2021
And:
- study shows its vaccines has the potential for durable immunity, phase 1 participants high levels of antibodies after 119 days
